Defining disease modification in PAH - Milan 2023

CDN Connection Issue

It appears that your current network does not allow connection to the CDN (Content Delivery Network) required for this service to function properly.

To resolve this issue, please try the following actions :

• Contact your network administrator : Inform them of this restriction so they can adjust the network settings accordingly.

• Use another network : Try connecting from a different network, such as another Wi-Fi network or a mobile connection.

We apologize for the inconvenience and thank you for your understanding.

International Congresses Defining disease modification in PAH

Disease modification in pulmonary arterial hypertension

Chair(s): Silvia Ulrich, Giovanni Viegi

Session type: Hot topics

Defining disease modification in PAH

Sandeep Sahay

EVENTS HOME

Replay
Slides

Previous presentation

Next presentation

Session content

Defining disease modification in PAH

Sandeep Sahay

Replay

Slides

Are approved PAH drugs disease-modifying?

Olivier Sitbon

Replay

Slides

Sotatercept for the treatment of PAH: an update

Marius M. Hoeper

Replay

Slides

Moving the field forward: novel pathways and targets for reverse remodelling

Soni Savai Pullamsetti

Replay

Slides

Discussion and Q&A

Replay

Session aims

to describe the goal for new disease-modifying treatment of pulmonary arterial hypertension (PAH); to review whether the currently available treatments really change PAH evolution; to describe new therapies affecting different signalling pathways that may modify disease progression.

CDN Connection Issue

The ERS International Congress 2023, Milan

#{title}